title: Oral folic acid enhances endothelial function in patients with hypercholesterolaemia receiving statins.
abstract: BACKGROUND
  Folic acid therapy has been shown to improve endothelial function in patients with familial hypercholesterolaemia via a possible antioxidant mechanism. Data on the possible role of folic acid in hypercholesterolaemic patients receiving statins are lacking. In the present study we tested the hypothesis that folic acid supplementation improves endothelial function in patients with hypercholesterolaemia and treatment with statins.
  
  
  METHODS
  Thirty-four hypercholesterolaemic patients receiving statins participated in the study; all subjects underwent measurement of endothelium-dependent, flow-mediated dilatation of the brachial artery and subsequently randomized to receive 5 mg of the folic acid (n=17) or placebo (n=17) for 4 weeks. Flow-mediated dilatation of the brachial artery was repeated at the end of the 4-week period.
  
  
  RESULTS
  Folic acid and placebo groups were comparable regarding age, sex, smoking, hypertension, coronary artery disease, obesity, family history and blood lipids. Folic acid administration resulted in an improvement of flow-mediated dilatation (4.7+/-3.2% to 7.1+/-3.1%, P=0.02), whereas there was no improvement after placebo administration (5.7+/-3.8% to 5.6+/-2.2%, ns). No significant change in nitrate-induced, endothelium- independent dilatation was observed after folic acid or placebo (ns).
  
  
  CONCLUSIONS
  Oral administration of folic acid (5 mg) for 4 weeks improves endothelial function in patients with hypercholesterolaemia treated with statins, with possible beneficial effects on the prognosis of these patients.
authors.affiliation: Vascular Laboratory, Department of Clinical Therapeutics, "Alexandra" Hospital, National & Kapodistrian University of Athens, Greece. lekakis@tellas.gr
authors.forename: John P
authors.initials: JP
authors.lastname: Lekakis
authors.forename: Christos M
authors.initials: CM
authors.lastname: Papamichael
authors.forename: Theodoros G
authors.initials: TG
authors.lastname: Papaioannou
authors.forename: Anna G
authors.initials: AG
authors.lastname: Dagre
authors.forename: Kimon S
authors.initials: KS
authors.lastname: Stamatelopoulos
authors.forename: Dimitrios
authors.initials: D
authors.lastname: Tryfonopoulos
authors.forename: Athanassios D
authors.initials: AD
authors.lastname: Protogerou
authors.forename: Stamatios F
authors.initials: SF
authors.lastname: Stamatelopoulos
authors.forename: Myron
authors.initials: M
authors.lastname: Mavrikakis
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D001916:Brachial Artery / Q000000981:diagnostic imaging / Q000187:drug effects* / Q000503:physiopathology; D019587:Dietary Supplements; D004311:Double-Blind Method; D004730:Endothelium, Vascular / Q000000981:diagnostic imaging / Q000187:drug effects / Q000503:physiopathology; D005260:Female; D005492:Folic Acid / Q000008:administration & dosage*; D006397:Hematinics / Q000008:administration & dosage*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D006937:Hypercholesterolemia / Q000188:drug therapy / Q000503:physiopathology*; D008297:Male; D008875:Middle Aged; D012039:Regional Blood Flow / Q000187:drug effects / Q000502:physiology; D014463:Ultrasonography; D014664:Vasodilation / Q000187:drug effects* / Q000502:physiology
chemical_list: D006397:Hematinics; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D005492:Folic Acid